Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey

Cambridge, UK, 12 September 2019Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, today announces that it has signed collaborations with world-renowned oncology research groups at the University of Oxford and the University of Surrey. These collaborations will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow-on pipeline of CD137-directed T cell enhancing programmes.

The Department of Oncology at the University of Oxford is one of the world’s leading cancer research centres. Dr Kerry Fisher’s group within this department, focuses on deepening our understanding of the tumour microenvironment to develop innovative new therapies for cancer patients.

Professor Hardev Pandha is a clinician scientist and a medical oncologist at the University of Surrey. He is head of the University’s Targeted Cancer Therapy research group, Director of the Surrey Cancer Research Institute and an expert in the management of patients with urological cancers. Professor Pandha leads a highly respected team with key interests in early phase clinical trials with targeted agents and novel therapies in translational settings.

Theodora Harold, CEO of Crescendo Biologics, commented:

“Professor Pandha and Dr Fisher each head up world-leading groups - it is a credit to the quality of our science to be able to collaborate with them. Their multidisciplinary and collaborative approaches to oncology research will allow Crescendo to gain a greater understanding of these difficult to treat cancers and support us to deliver first in class, targeted T cell therapies.”

Dr Kerry Fisher, Department of Oncology, University of Oxford, commented:

“We look forward to working with Crescendo to further explore and understand the mechanisms driving the development of cancers and applying our group’s translational expertise to advance Crescendo’s novel Humabody® programmes.”

Professor Hardev Pandha, University of Surrey, added:

“We are delighted to be exploring the potential of Crescendo’s novel, targeted, T cell co-stimulatory molecules to deliver therapeutic benefit to patients with high unmet medical need.”

- ENDS -

Issued for and on behalf of Crescendo Biologics by Instinctif Partners.
For more information please contact:

Crescendo Biologics
Theodora Harold, CEO
+ 44 (0)1223 497140

The University of Oxford
Chris McIntyre, Media Relations Manager
+44 (0)1865 270 046

Instinctif Partners
Dr Christelle Kerouedan, Melanie Toyne-Sewell
+ 44 (0)20 7457 2020

The University of Surrey
Press Office
+44 (0)1483 68 8914

About Crescendo Biologics
Crescendo Biologics is a T cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA-HSA trispecific for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity and is on track to enter the clinic in 2020.

The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website:

About the University of Oxford, Medical Sciences Division
Oxford University’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine and life sciences, and it is home to the UK’s top-ranked medical school. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.

About the University of Surrey
The University of Surrey is one of the UK’s top higher education institutions and was recognised as the University of the Year in The Times and Sunday Times Good University Guide 2016. With 125 years of academic heritage since our founding in Battersea, and 50 years of world-class teaching and research in Guildford, the University of Surrey is the intellectual home for more than 16,000 students, 117,000 alumni and over 3,000 staff.

Freedom of thought, pursuit of academic excellence, and the advancement and application of knowledge underpin the wonderful things happening here. Our mission is to transform lives and enrich society through outstanding teaching and learning, pioneering research and impactful innovation.

The University of Surrey has been recognised by four Queen’s Anniversary Prizes for Further and Higher Education and is a destination of choice for higher learning in subjects ranging from Engineering to the Arts. As a global University, we are proud of our strong partnerships with internationally leading institutions and businesses, while being firmly engaged with our local community in Guildford and Surrey. We are committed to educating the next generation of professionals and leaders, and to providing thought leadership and innovation to address global challenges and contribute to a better tomorrow for the world.

Back to news